| Bioactivity | Tusamitamab ravtansine (SAR-408701) is a DM4 (HY-12454) anti-CEACAM5 antibody-drug conjugate (ADC). Tusamitamab ravtansine is composed of a humanized monoclonal antibody that binds carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5) and a cytotoxic maytansinoid that selectively targets CEACAM5-expressing tumor cells[1]. |
| Name | Tusamitamab ravtansine |
| CAS | 2254086-60-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gazzah A, et al. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022 Apr;33(4):416-425. |